SAN ANTONIO — A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer. pCR, ...

Breast density is a strong and potentially modifiable breast cancer risk factor. Almost everything we know about breast density has been derived from mammography, and therefore, very little is known ...

Add Yahoo as a preferred source to see more of our stories on Google. We may not live in a world with robot doctors, but AI technology has become advanced enough to improve the work of radiologists.

Researchers from Queen Mary University London and Emory University used a novel AI-based analytic tool to better understand how tumor infiltrating lymphocytes (TILs) can predict which cases of Ductal ...

MinnPost’s journalists are out in the community to report on the things that are happening in Minnesota. Your support right now will help fund their work AND keep our news paywall-free. A new test ...

Scientists at the UK's National Physical Laboratory (NPL) have demonstrated the first in-person measurements of breast tissue using an innovative new detection technique, which has the potential to ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College of ...

Breast augmentation is surgery, of course, and comes with risks, which can include unnatural-looking results, painful hardening of scar tissue, and reoperation. (Detailed information is at fda.gov and ...

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life. It's consistent with the idea that it is a ...

Breast cancer is the most common cancer among women worldwide. According to the 2020 Global Cancer Burden data released by the International Agency for Research on Cancer (IARC), the number of newly ...

Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α) No significant ...